Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Agomelatine for sleep disturbance, depression and anxiety in systemic lupus erythematosus
TCTR20171010002Enrolling by invitation
- Sponsor
- N/A
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in systemic lupus erythematosus (SLE), sleep disorder, major depressive disorder (MDD) and 1 more comparing Agomelatine with Placebo (2 arms). Primary endpoints: Sleep disturbance improvement, Depression improvement and 1 more. Started Oct 2017; status: enrolling by invitation.
02
Drugs
agomelatine
03
Conditions
systemic lupus erythematosus (SLE)sleep disordermajor depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on TCTR20171010002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20171010002.